Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Consensus Target Price from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given an average rating of “Buy” by the seven brokerages that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $65.00.

A number of equities research analysts have issued reports on ARCT shares. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday. BTIG Research began coverage on shares of Arcturus Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $41.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th.

Institutional Trading of Arcturus Therapeutics

Several large investors have recently added to or reduced their stakes in ARCT. Sumitomo Mitsui Trust Group Inc. increased its holdings in Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after purchasing an additional 712,650 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in Arcturus Therapeutics by 129.7% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company’s stock valued at $14,409,000 after purchasing an additional 479,482 shares in the last quarter. Empire Life Investments Inc. acquired a new stake in Arcturus Therapeutics in the 3rd quarter valued at $3,498,000. ARK Investment Management LLC increased its holdings in Arcturus Therapeutics by 6.9% in the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock valued at $48,765,000 after purchasing an additional 136,074 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Arcturus Therapeutics by 6.8% in the 4th quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company’s stock valued at $28,587,000 after purchasing an additional 107,635 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Up 10.0 %

ARCT stock opened at $18.05 on Thursday. The company has a market cap of $488.97 million, a price-to-earnings ratio of -8.13 and a beta of 2.62. The business has a fifty day simple moving average of $17.01 and a 200-day simple moving average of $18.95. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.